KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
British Journal of Cancer, 05/25/2012
Kawamoto Y et al. – Because the mutational statuses of predictive biomarker genes were not altered by FOLFOX therapy, specimens from both primary tumours and post-FOLFOX tumour metastases might serve as valid sources of DNA for known genomic biomarker testing.
A total of 63 lesions (23 baseline primary, 18 metastatic and 24 post-treatment metastatic) from 21 patients who were treated with FOLFOX as adjuvant therapy for stage III/IV colorectal cancer following curative resection were examined.
The DNA samples were obtained from formalin-fixed paraffin-embedded specimens, and KRAS, NRAS, BRAF and PIK3CA mutations were evaluated.
The numbers of primary lesions with wild-type and mutant KRAS codons 12 and 13 were 8 and 13, respectively.
The mutational status of KRAS remained concordant between the primary tumours and the post-FOLFOX metastatic lesions, irrespective of patient background, treatment duration and disease-free survival.
Furthermore, the mutational statuses of the other genes evaluated were also concordant between the primary and metastatic lesions.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.